April 25th 2025
Sophisticated colloidal oat emollients show promise in effectively managing pediatric atopic dermatitis, enhancing skin hydration and reducing flare-ups in infants.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
FDA clamps down hard to tighten Accutane access
September 6th 2005National report -- The Food and Drug Administration (FDA) has placed unprecedented restrictions on the acne drug Accutane (Roche) by requiring patients who use it, as well as those who prescribe and dispense it, to enroll in a national registry and follow other stringent rules.
Certain pediatric skin diseases more likely in children with skin of color
September 1st 2005Children with skin of color are also especially likely to develop hypo- or hyperpigmentary changes after resolution of lesions of a dermatosis or secondary to other forms of skin trauma, including treatments administered for skin disorders.
TriLuma combination effective for PIH
September 1st 2005Kissimmee, Fla. — With recent developments in the treatment of hyperpigmentation, Dr. Roger Ceilley, clinical professor of dermatology at the University of Iowa and past president of the American Academy of Dermatology and the American Society for Dermatologic Surgery, provided further insight into the management of post-inflammatory hyperpigmentation.
Hormonal role in pigmentation studied
September 1st 2005Tokyo — There is the possibility that sex hormones and sex hormone-binding globulin (SHBG) may regulate melanogenesis, a recent finding that may change the way in which pigmentation is viewed, according to Taketsugu Tadokoro, M.D., Ph.D., director, department of dermatology, Osaka National Hospital, Osaka-shi, Japan.
Tattoos temporary, reactions persist
August 1st 2005New Orleans — The increased popularity of temporary, dark henna body tattoos appears to be providing dermatologists with more cases of allergic contact dermatitis as well as a new area in which to counsel patients about safety. According to Mukta Sachdev, M.D., F.A.A.D., adverse reactions to certain types of temporary henna tattoos are on the increase, and dermatologists have the opportunity to educate and advise patients about potential risks associated with this form of body art.